| Document |
Document Title |
|
JP2602964B2 |
The present invention provides a novel prostaglandin analogue of the following formula: and a method for its preparation.o
|
|
JPH09504029A |
Compounds of the formula where the hatched lines indicate alpha ( alpha ) configuration, a solid triangle is used to indicate beta ( beta ) configuration, lines on both sides of a double bond indicate cis (Z) configuration, and lines on ...
|
|
JP2597629B2 |
A stabilized 13,14-dihydro-15-ketoprostaglandin composition comprising an intimate mixture of a) a therapeutically effective amount of at least one compound selected from 13,14-dihydro-15-ketoprostaglandins and b) at least one compound s...
|
|
JP2597649B2 |
The present invention provides a tracheobronchodilator comprising 15-keto-PGEs, reduced in stimuli against bronchi and other side effects.
|
|
JP2596575B2 |
Process for the production of alpha -hydroxy-bicyclo[3.3.0]octane derivatives of formula (I), where A is the double-bound residue -O-X-O-, X having the notation of a straight or branched-chain alkalin with 1-7 C atoms or the residue =CH-...
|
|
JP2593540B2 |
PCT No. PCT/DE88/00149 Sec. 371 Date Nov. 13, 1989 Sec. 102(e) Date Nov. 13, 1989 PCT Filed Mar. 11, 1988 PCT Pub. No. WO88/07050 PCT Pub. Date Sep. 22, 1988.The invention relates to a process for the production of (+)-bicyclo[3.3.0]octa...
|
|
JPH09502964A |
The present invention relates to cyclopentane heptanoic or cyclopentane heptenoic acid, 2-hydrocarbyl sulfonamidomethyl, and derivatives thereof, useful as therapeutic agents. In particular, the therapeutic agents of this invention are u...
|
|
JP2592204B2 |
PURPOSE: To provide an intraocular tension depressant little in side effect, excellent in therapeutic effect, useful for curing the intraocular tension rise concomitant with glaucoma or hypertension, containing, as active ingredient, a d...
|
|
JPH09501943A |
PCT No. PCT/EP94/02855 Sec. 371 Date May 29, 1996 Sec. 102(e) Date May 29, 1996 PCT Filed Aug. 29, 1994 PCT Pub. No. WO95/06634 PCT Pub. Date Mar. 9, 1995The invention relates to 9-chloro-prostaglandin derivatives of formula I (I) in whi...
|
|
JP2579193B2 |
|
|
JPH0920788A |
To obtain a new vinyltin compound capable of producing rostaglandins useful as e.g. a swine-oxytocic with a few processes and an inexpensive reaction reagent, by reaction of a protecting group-bearing specific epoxysilicon compound with ...
|
|
JP2571250B2 |
|
|
JPH08310956A |
PURPOSE: To obtain the subject inhibitor containing a specific active ingredient, strongly suppressing chemotaxis caused by a chemokine such as monocyte migration factor MCP-1/MCAF, etc., and/or migration of smooth muscle cell of blood v...
|
|
JP2543396B2 |
|
|
JPH08246977A |
PURPOSE: To perform further precise control of an injection amount of fuel and an injection timing. CONSTITUTION: A rotation angle sensor 120 is provided with a sensor body 123, containing a magnet 121 and a coil 122, and a magnetic flux...
|
|
JP2536026B2 |
|
|
JP2536516B2 |
NEW MATERIAL:A compound shown by formula I {R<1> is 1-10C aliphatic group (which may contain 0-3 unsaturated bonds and may be replaced with lower alkoxy or lower alkoxycarbonyl) or H; X is H or OH-protecting group; Y is group shown by fo...
|
|
JP2529095B2 |
PURPOSE: To obtain the subject new prostaglandin E2 having strong uterus contraction action and suppressing the embedding of egg and useful as an uterus contracting agent or a medicine for artificial abortion, etc. CONSTITUTION: 13, 14-D...
|
|
JPH08208598A |
PURPOSE: To obtain the subject composition markedly improved in the stability of prostaglandin compounds, high in safety, thus useful as a medicine, etc., comprising a prostaglandin compound and a carboxylic acid diglyceryl ester. CONSTI...
|
|
JPH08208599A |
PURPOSE: To obtain the subject physically stable compound expressed by a specific formula, easy to purify and handle, and having pharmacological action on various kinds of nephrotic diseases and ischemic cardiopathy, etc. CONSTITUTION: T...
|
|
JP2515458B2 |
PURPOSE: To obtain a wound curing promoter, especially a curing promoter for corneal damage containing a 15-keto-prostaglandin compound as an active ingredient. CONSTITUTION: A wound curing promoter containing a 15-keto-prostaglandin com...
|
|
JPH08169832A |
PURPOSE: To obtain a skin application composition containing a 7- thiaprostaglandin compound, useful as an agent for the treatment of cutaneous ulcer having the lesion part near the surface of the skin, having stability and enabling quic...
|
|
JP2511579B2 |
A compound of the formula: wherein L and M are hydrogen atom, hydroxy, lower alkyl, hydroxy(lower)alkyl or oxo, provided that at least one of L and M is not hydrogen atom and that the five-membered ring may have one or two double bonds, ...
|
|
JP2503073B2 |
|
|
JPH08143542A |
PURPOSE: To obtain a new unsaturated aldehyde derivative, useful as an intermediate for medicines, agrochemicals, perfumes, analytical reagents, etc., and capable of industrially, advantageously and readily producing prostaglandin deriva...
|
|
JPH0892096A |
PURPOSE: To obtain an inhibitor for propagation or migration of vascular smooth muscle cell containing specific isocarbacylines and expectable of availability to prevent or cure, etc., of restenosis after percutaneous coronary arteriopla...
|
|
JPH08502495A |
Compounds of the formula where the dotted line represents a bond or the absence of a bond, the wavy lines represent bonds which are either in cis or trans configuration; R1 represents H, or CO-R2 where R2 is lower alkyl of 1 to 6 carbons...
|
|
JPH0819040B2 |
The phenylalkan(en)oic acids of the formula: wherein the substituants are defined as in the disclosure, possess an antagonism on leukotriene B4, and therefore, are useful for the prevention and treatment of several diseases induced by le...
|
|
JPH08501546A |
This invention relates to a prostaglandin-bisphosphonate compound of the formula: and its pharmaceutically acceptable salts. The claimed compounds are effective as delivery agents of prostaglandins to treat osteoporosis and related bone ...
|
|
JPH089543B2 |
|
|
JPH085836B2 |
|
|
JPH08500597A |
The invention concerns 9-chloroprostaglandin esters and amides of general formula (I), methods of preparing them and their use as drugs.
|
|
JPH07116134B2 |
NEW MATERIAL:The compound of formula I [the double line is cis or trans double bond; G<1> is -CO2R<5> (R<5> are H, 1-10C alkyl, etc.), etc.; R<1> is H, methyl, etc.; R<2> is unsubstituted 5-8C alkyl, (substituted) alicyclic group, etc.; ...
|
|
JPH07116135B2 |
|
|
JPH07116136B2 |
|
|
JPH07113012B2 |
|
|
JPH07309833A |
PURPOSE: To obtain the new subject compound having strong and long lasting intraocular tension-reducing activity, free from side effect and useful as an agent for prophylaxis and/or treatment of glaucoma. CONSTITUTION: This compound is a...
|
|
JPH07107020B2 |
Cyclodextrin clathrates of carbacyclin analogs of general Formula I (I) wherein R1 is hydrogen, alkyl or alkenyl of up to 10 carbon atoms, A is a -CH2CH2-, trans-CH=CH-, or -C 3BOND C- group, W is a free or functionally modified hydroxym...
|
|
JPH07103096B2 |
|
|
JPH07285930A |
PURPOSE: To provide a new PGE1 analogue having a more selective and stronger antiulcer activity than those of the known PGE1 analogues and excellent in persistence. CONSTITUTION: A compound of formula I (A is O, NH; B is -NHCO-, -CONH-, ...
|
|
JPH0796497B2 |
|
|
JPH0794451B2 |
|
|
JPH0791218B2 |
The present invention relates to a new prostagrandine I analogous compounds represented by the following formula (I) and (II). wherein R1 is a hydrogen atom or alkyl group, at least one of R2 and/or R2' are a halogen atom, an alkyl group...
|
|
JPH07238068A |
PURPOSE: To obtain a new prostaglandin E1 analog, having suppressing actions on blood platelet agglutination and vasodepressor activities and useful for treating, etc., peripheral circulatory disorder. CONSTITUTION: This compound is expr...
|
|
JPH07233145A |
PURPOSE: To obtain a new prostaglandin E1 amide homologue which is useful for treating digestive ulcer because it has high durative actions to protect cells and inhibit the secretion of gastric juice. CONSTITUTION: A compound of formula ...
|
|
JPH0772170B2 |
This invention relates to a process for making a compound of formula Iin the form of a stereoisomer or mixture thereof, wherein R is hydrogen, lower alkyl; X is hydrogen, halo, trifluoromethyl, lower alkyl or lower alkoxy, and the wavy l...
|
|
JPH0768158B2 |
PCT No. PCT/DE86/00483 Sec. 371 Date Aug. 7, 1987 Sec. 102(e) Date Aug. 7, 1987 PCT Filed Nov. 28, 1986 PCT Pub. No. WO87/03582 PCT Pub. Date Jun. 18, 1987.The invention relates to a process for the production of (5-chloro-3-hydroxycyclo...
|
|
JPH07188025A |
PURPOSE: To obtain a medicine inhibiting cell migration caused by a chemokine, e.g. monocyte migration factor MCP-1/MCAF, comprising a specific prostaglan din E and/or its enantiomer as an effective component. CONSTITUTION: An inhibitor ...
|
|
JPH0764808B2 |
The invention relates to 9-halo-15-cycloalkyl prostaglandin derivatives of Formula I (I) wherein R1 is hydrogen or methyl, R2 is fluorine or chlorine, n is 0 or 1, and, if R1 is hydrogen, the salts thereof with physiologically compatible...
|
|
JPH0764733B2 |
|
